MiNK Therapeutics, Inc. (INKT) Tops Q2 EPS by 3c

MiNK Therapeutics, Inc. (NASDAQ: INKT) reported Q2 EPS of ($0.07), $0.03 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on MiNK Therapeutics, Inc. (INKT) click here.

You May Also Be Interested In

• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• UPS invests $48 million in 27 cold-chain freight facilities globally
• BMO Capital on Darden Restaurants (DRI): 'Modestly Lowering FY4Q26 Estimates'